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OBJECTIVE — Toidentifyfactorsinpatientswithtype2diabetesandA1C7.0%associated
with attainment of A1C 7.0%.
RESEARCH DESIGN AND METHODS — We used a prospective registry of 5,280
Canadian patients in primary care settings enrolled in a 12-month glycemic pharmacotherapy
optimization strategy based on national guidelines.
RESULTS — At close out, median A1C was 7.1% (vs. 7.8% at baseline) with 48% of subjects
achieving A1C 7.0% (P  0.0001). Older patients of Asian or black origin, those with longer
diabetesduration,thosewithlowerbaselineA1C,BMI,LDLcholesterol,andbloodpressure,and
those on angiotensin receptor blockers and a lower number of antihyperglycemic agents, were
more likely to achieve A1C 7.0% at some point during the study (all P  0.0235). Access to
private versus public drug coverage did not impact glycemic target realization.
CONCLUSIONS — Patient demography, cardiometabolic health, and ongoing pharmacother-
apy, but not access to private drug insurance coverage, contribute to the care gap in type 2 diabetes.
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T
reatment gaps in achieving A1C
targets persist (1,2). Our goal was
to identify, in a type 2 diabetic pa-
tient registry, factors that contribute to
attaining the A1C target of 7.0% rec-
ommended by the 2003 Canadian Dia-
betes Association (CDA) clinical
practice guidelines (3).
RESEARCH DESIGN AND
METHODS— The “Time 2 Do More”
(T2DM) protocol underwent ethics ap-
proval. Physicians were educated on the
2003 CDA guidelines, which focused on
A1C7.0%,fastingplasmaglucose7.0
mmol/l, LDL cholesterol 2.5 mmol/l,
total-to-HDL cholesterol ratio 4.0, and
blood pressure 130/80 mmHg.
The ﬁnal 5,280 insulin-naive pa-
tients, enrolled from 378 primary care
practices across nine Canadian prov-
inces between March 2006 and Septem-
ber 2007, had A1C 7.0% and a
clinical diagnosis of type 2 diabetes.
Participation was voluntary, and writ-
ten informed consent was mandatory.
Protocol subclassiﬁcation into private
(unencumbered access to any antihy-
perglycemic agent [AHA]) or public
(access only to AHA approved by pro-
vincial formulary programs) insurance
groups was met by 4,797 patients (376
sites, nine provinces).
Physicians monitored and directed
therapies using their best clinical judg-
ment. The protocol neither mandated the
frequency or timing of clinical visits nor
dictated the speciﬁc medications or doses
to be prescribed. Subjects not at A1C tar-
get at follow-up were encouraged to have
their antihyperglycemic treatment intensi-
ﬁed. Detailed feedback provided after visit
twoallowedphysicianstoidentifythosenot
at target and/or not receiving guideline-
recommended treatments. Laboratory val-
ues were obtained as part of routine clinical
care.
A generalized estimating equation
model was ﬁtted to assess the association
betweenincreaseinnumberofprescribed
AHAs at each visit and changes in A1C
target achievement. Model selection was
based on the quasi-likelihood under the
independence model criterion (4). The ﬁ-
nal model was used to assess the associa-
tion between drug insurance coverage
and changes in target achievement.
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men and 74.9% Caucasian. Median age,
baseline A1C, LDL cholesterol, and blood
pressure were 60 years, 7.8%, 2.3 mmol/l,
and 130/80 mmHg, respectively. Median
duration of diabetes was 6 years with 18,
5.5, and 4.8% of the cohort reporting prior
coronary artery, peripheral vascular, and
cerebrovascular disease events, respec-
tively. Sequential declines in A1C (median
7.1% at close out; P  0.0001) paralleled
progressiveincreasesinA1C7.0%attain-
ments(P0.0001;supplementaryTable1
availableathttp://care.diabetesjournals.org/
cgi/content/full/dc10-0440/DC1). Of the
3,122 patients who had A1C measured at
all four visits, 35.9% did not achieve A1C
7.0% at any time during the study. Me-
dianfastingplasmaglucose,lipidlevels,and
bloodpressureimprovedtemporally,asdid
the percentages of patients optimally man-
aged (supplementary Table 1).
The number of patients on multiple
AHAs increased whereas the number on
monotherapy decreased during the study
(supplementary Table 2). After adjusting
forageandthecovariatesthatweresignif-
icant in the multivariable model, the
number of AHAs prescribed at each pre-
vious visit remained signiﬁcantly associ-
ated with target achievement during the
study (Table 1). Older patients of Asian
origin or blacks, those with longer diabe-
tes duration, those with lower baseline
A1C, BMI, LDL cholesterol, or blood
pressure, and patients on angiotensin re-
ceptor blockers (ARBs) and with a lower
number of AHAs prescribed, were more
likely to achieve A1C target at some period
duringthestudy(allP0.0235).Differen-
tial access to drug insurance coverage was
notassociatedwithchangesinglycemictar-
get achievement in univariate (P  0.64)
and multivariable (P  0.24) analyses.
CONCLUSIONS— In this physician
practice–optimization strategy focused
on optimizing AHA regimens, 50% of
the patients recorded A1C 7.0% 12
months after entering the study. Multiva-
riable analysis revealed that A1C 7.0%
was associated with age, ethnicity, base-
line A1C, LDL cholesterol, blood pres-
sure, duration of diabetes, use of ARBs,
and number of AHAs prescribed.
Although the predictive values of de-
mography and cardiometabolic health on
A1Cimprovementswerenotunexpected,
thesuboptimalsuccessinA1Crealization
is intriguing because a quarter of the pa-
tients were already or subsequently
placedonthreeormoreAHAsatbaseline.
Clinical inertia (5,6) in the form of de-
layed insulin introduction was likely con-
tributory. At the time of the study,
although there was evidence that tight
glycemic control can ameliorate micro-
vascular complications (7,8), there were
no similar data for macrovascular risk,
which may have factored into physician
decision making. The paradox that pa-
tients on a lower number of AHAs were
more likely to achieve the A1C target
probably stemmed from patients with
“more severe” diabetes being more likely
to be prescribed multiple AHAs.
Our ﬁnding that private insurance–
enabled unencumbered access to any
AHA did not impact on A1C 7.0%
achievement must be interpreted cau-
tiously because at the time of this study,
thiazolidinediones were the only major
class of AHAs not covered by the majority
of Canadian provincial formularies. Nota-
bly, patients with public-only coverage
were less likely than those with private in-
surance to be on thiazolidinediones at the
beginningofthestudy,butthisdiscrepancy
was no longer evident after visit two.
This study has several limitations. An
element of physician selection bias is likely
because a quarter of the patients at baseline
eitherwerealreadyonorweresubsequently
placed on three or more AHAs. Although
only 59% of the patients had complete data
for all four visits, study participation may
have triggered improvements. Neither life-
style modiﬁcations and social support sys-
tems nor comanagement by a specialist was
Table 1—Factors associated with temporal changes in A1C <7.0% achievement
Unadjusted OR (95% CI) P Adjusted OR (95% CI) P
Men vs. women 0.996 (0.992–1.076) 0.93
Age (per 5 years higher) 1.029 (1.012–1.045) 0.0006 1.024 (1.003–1.046) 0.0235
Ethnicity (Caucasian as reference)
East and South-East Asian 0.764 (0.667–0.874) 0.0001 0.715 (0.606–0.842) 0.0001
South Asian 0.592 (0.500–0.701) 0.0001 0.641 (0.528–0.779) 0.0001
Black 0.651 (0.519–0.816) 0.0002 0.71 (0.548–0.920) 0.0095
Aboriginal Canadian native/Inuit 0.699 (0.517–0.945) 0.02 0.867 (0.604–1.244) 0.44
Others 0.945 (0.710–1.260) 0.701 0.903 (0.657–1.241) 0.53
Unknown 0.670 (0.512–0.876) 0.0035 0.651 (0.464–0.913) 0.0129
Insurance coverage (private vs. public) 0.979 (0.895–1.070) 0.64
Baseline A1C (per 1% lower) 1.368 (1.301–1.438) 0.0001 1.344 (1.273–1.419) 0.0001
LDL cholesterol (per 1 mmol/l lower)* 1.412 (1.340–1.487) 0.0001 1.349 (1.275–1.427) 0.0001
Systolic blood pressure (per 10 mmHg lower)* 1.121 (1.093–1.151) 0.0001 1.101 (1.063–1.140) 0.0001
Diastolic blood pressure (per 10 mmHg lower)* 1.202 (1.154–1.251) 0.0001 1.09 (1.031–1.153) 0.0024
Baseline BMI (per 5 kg/m
2 lower) 1.041 (1.013–1.071) 0.0044 1.044 (1.008–1.081) 0.0158
Duration of type 2 diabetes (per 5 years lower) 1.239 (1.193–1.287) 0.0001 1.451 (1.375–1.532) 0.0001
Smoker (No vs. Yes) 1.071 (0.948–1.210) 0.27
Exercise vs. sedentary lifestyle 1.033 (0.956–1.115) 0.41
Family history of diabetes (No vs. Yes) 1.086 (1.007–1.172) 0.033
Pharmacotherapy
Number of AHAs (per unit lower)* 1.176 (1.129–1.224) 0.0001 1.326 (1.256–1.399) 0.0001
Statin (Yes vs. No) 1.223 (1.112–1.344) 0.0001
ACE inhibitor (Yes vs. No) 1.052 (0.976–1.135) 0.19
ARB (Yes vs. No)* 1.241 (1.145–1.346) 0.0001 1.246 (1.133–1.370) 0.0001
-blocker (Yes vs. No) 1.090 (0.993–1.198) 0.072
*Time-dependent variables. OR, odds ratio.
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scriptions and therapeutic proﬁles was
drawn from case report forms rather than
pharmacy records.
Our study nonetheless has notable
strengths.Thedatawerefromalargecohort
that included both sexes and various eth-
nicities with differential drug insurance
coverage. The longitudinal registry design
resembles a “real world” setting without the
typicalclinicaltrialselectionbias.Ourstudy
was initiated and completed before the re-
sults of the major outcome trials that have
fuelled the controversies of how intensive
glycemic lowering impacts severe hypogly-
cemia and cardiovascular events (9–12)
werepublishedandthusmayserveasause-
ful benchmark for future comparisons of
how practice patterns may evolve.
Inconclusion,inalargeCanadianco-
hort of type 2 diabetic patients not meet-
ingglycemictargets,nearly50%achieved
the guideline-recommended A1C 7.0%
target after 12 months in a physician-
basedpracticeoptimizationstrategy.Suc-
cessinrealizingtargetA1Cwasassociated
with patient age, ethnicity, baseline A1C,
LDLcholesterol,bloodpressure,duration
of diabetes, number of AHAs prescribed,
and use of ARBs, but not with the type of
drug insurance coverage.
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